Biopharmaceutical company Kexing announced that its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., successfully completed the first subject in the phase I clinical trial of its "GB08 injection".
科兴制药：GB08注射液I期临床试验完成首例受试者入组
Kexing biopharm: the first subject has been enrolled in the phase I clinical trial of GB08 injection.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.